Patents by Inventor Steven Laplante

Steven Laplante has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240408064
    Abstract: There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS.
    Type: Application
    Filed: October 14, 2022
    Publication date: December 12, 2024
    Applicant: GENETOLEAD INC.
    Inventors: Luc FARMER, Steven LAPLANTE, Yann AYOTTE, Sacha Thierry LARDA, Saba ALAPOUR, Simon WOO, David BENDAHAN, Maria DENK, Majid FARAHANI, Mustapha IDDIR
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20140296228
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: February 28, 2014
    Publication date: October 2, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8710230
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 29, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8354429
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: January 15, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rebekah J. Carson, Rene Coulombe, Lee Fader, Teddy Halmos, Stephen Kawai, Serge Landry, Steven LaPlante, Sebastien Morin, Mathieu Parisien, Marc-Andre Poupart, Bruno Simoneau
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8338441
    Abstract: Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 25, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Christiane Yoakim, Murray Bailey, Francois Bilodeau, Rebekah Carson, Lee Fader, Stephen Kawai, Sebastien Morin, Carl Thibeault, Bruno Simoneau, Simon Surprenant, Youla Tsantrizos, Steven Laplante
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20110028464
    Abstract: Compounds of formula I: wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: November 3, 2008
    Publication date: February 3, 2011
    Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBH
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, François Bilodeau, Rebekah J. Carson, Lee Fader, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven Laplante, Bruno Simoneau
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20100311735
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: September 11, 2008
    Publication date: December 9, 2010
    Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBH
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20100292227
    Abstract: Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 18, 2010
    Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBH
    Inventors: CHRISTIANE YOAKIM, MURRAY BAILEY, FRANCOIS BILODEAU, REBEKAH CARSON, LEE FADER, STEPHEN KAWAI, SEBASTIEN MORIN, CARL THIBEAULT, BRUNO SIMONEAU, SIMON SURPRENANT, YOULA TSANTRIZOS, STEVEN LAPLANTE
  • Hepatitis C Virus NS5B polymerase inhibitor binding pocket
    Patent number: 7386398
    Abstract: The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: June 10, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: René Coulombe, Pierre Beaulieu, Eric Jolicoeur, George Kukolj, Steven Laplante, Marc-André Poupart
  • Hepatitis C virus NS5B polymerase inhibitor binding pocket
    Publication number: 20050003348
    Abstract: The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.
    Type: Application
    Filed: May 7, 2004
    Publication date: January 6, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rene Coulombe, Pierre Beaulieu, Eric Jolicoeur, George Kukolj, Steven Laplante, Marc-Andre Poupart